Clinical Trial

Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy. Previous clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion is safe and whether it can further improve cardiac function in this patient population.
Protocol Amendment History 2 changes
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
critical Recruitment opened 2026-07-03
Trial Details
NCT Number NCT07516288
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Dilated Cardiomyopathy (DCM), Heart Failure
Enrollment 5 participants
Start Date 2026-05-11
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02